文献速递肺外科

亚洲患者非小细胞肺癌术后复发治疗进展及其对生存的影响

Advances in the treatment of postoperative recurrence of non-small cell lung cancer and their impact on survival in Asian patients.
PubMed 文献 · J Thorac Cardiovasc Surg · 2022-08-25

这项单中心回顾性研究纳入2008至2018年接受肺叶或更大范围完整病理切除的非小细胞肺癌患者2254例,中位随访5.1年,分析术后复发后酪氨酸激酶抑制剂和免疫治疗对生存的影响。443例(19.7%)术后复发,EGFR/ALK阳性组生存优于未检测或未知组(中位4.7 vs 2.1年,P<.01);2010至2018年复发后2年生存显著改善(APC 4.2,95%CI 1.5-7.0),无驱动基因突变组2年生存显著改善(APC 13.5,95%CI 5.4-22.2)且免疫治疗使用呈增加趋势(APC 23.0,95%CI -5.9至60)。

要点

  • 术后复发患者中位复发时间1.1年,EGFR阳性191例(43.1%),ALK阳性13例(2.9%),未检测或未知239例(54.0%)。
  • EGFR/ALK阳性组复发后生存优于未检测或未知组(中位4.7 vs 2.1年,P<.01)。
  • 无驱动基因突变组2013年后2年生存显著改善且免疫治疗使用呈增加趋势。

核心结论

  • 非小细胞肺癌术后复发后生存自2010年以来显著改善;无驱动基因突变患者使用免疫治疗可能促进了该改善;有驱动基因突变患者使用研究期间前已引入的TKI预后仍良好。

研究设计与样本

  • 单中心回顾性研究,纳入2008至2018年接受肺叶或更大范围完整病理切除的非小细胞肺癌患者2254例,中位随访5.1年。
  • 采用Joinpoint(美国国家癌症研究所)和Cox回归分析生存趋势及TKI/免疫治疗的作用。

主要发现

  • 术后复发443例(19.7%),中位复发时间1.1年;EGFR阳性191例(43.1%),ALK阳性13例(2.9%),未检测或未知239例(54.0%)。
  • 多变量分析中,年龄、复发时间、腺癌、有症状复发、针对复发的任何治疗、使用EGFR TKI、使用ALK TKI及使用免疫治疗为显著预后因素。
  • EGFR/ALK阳性组生存显著优于未检测或未知组(中位4.7 vs 2.1年,P<.01)。
  • 2010至2018年间,复发后2年生存显著改善(APC 4.2,95%CI 1.5-7.0)。
  • 亚组分析中,EGFR/ALK阳性组2年生存变化及TKI使用随时间均无显著变化;未检测或未知组2013年后2年生存显著改善(APC 13.5,95%CI 5.4-22.2)且免疫治疗使用呈增加趋势(APC 23.0,95%CI -5.9至60)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We investigated the effect of tyrosine kinase inhibitors (TKIs) and immunotherapy on survival after postoperative recurrence of non-small cell lung cancer (NSCLC). METHODS: This single-center retrospective study included patients with NSCLC who underwent lobectomy or more with complete pathological resection between 2008 and 2018 (N = 2254). Median follow-up was 5.1 years. Survival trends and the effect of TKIs/immunotherapy were analyzed using Joinpoint (National Cancer Institute) and Cox regression. RESULTS: In 443 (19.7%) postoperative recurrences, median time to recurrence was 1.1 years; epidermal growth factor receptor mutation (EGFR+), 191 (43.1%); anaplastic lymphoma kinase rearrangement (ALK+), 13 (2.9%); not detected or unknown (ND), 239 (54.0%). In multivariable analysis, age, time to recurrence, adenocarcinoma, symptomatic recurrence, any treatment for recurrence, use of the epidermal growth factor receptor TKI, use of the anaplastic lymphoma kinase TKI, and use of immunotherapy were significant prognostic factors. Survival was significantly better in the EGFR+/ALK+ group than in the ND group (median, 4.7 vs 2.1 years; P < .01). Between 2010 and 2018, 2-year postrecurrence survival improved significantly (annual percentage change [APC], 4.2; 95% CI, 1.5-7.0). In subset analyses, neither change in 2-year survival nor TKI use was significant over time in the EGFR+/ALK+ group, but the ND group experienced significant improvement in 2-year survival (APC, 13.5; 95% CI, 5.4-22.2) and increasing trend in immunotherapy use (APC, 23.0; 95% CI, -5.9 to 60) after 2013. CONCLUSIONS: Survival after postoperative recurrence of NSCLC has improved significantly since 2010. Use of immunotherapy in patients without driver mutations may have contributed to that improvement. Prognosis in patients with driver mutations remains favorable with the TKIs introduced before the study period.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Hashimoto K, Ariyasu R, Ichinose J, et al. Advances in the treatment of postoperative recurrence of non-small cell lung cancer and their impact on survival in Asian patients. J Thorac Cardiovasc Surg. 2022. PMID: 36137840. doi:10.1016/j.jtcvs.2022.08.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。